Rapport Therapeutics terminates ATM equity offering program; no shares sold

Rapport Therapeutics, Inc.

Effective Sept 8, 2025, terminated the ATM prospectus under the S-3 registration statement.
Sales Agreement with Leerink and Cantor remains in effect but no sales without new filing.
No shares of common stock were issued or sold under the program as of termination date.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.